Tema Etfs LLC acquired a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 148,167 shares of the company's stock, valued at approximately $1,728,000. Tema Etfs LLC owned approximately 0.15% of Intellia Therapeutics at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Sterling Capital Management LLC lifted its position in shares of Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after purchasing an additional 2,867 shares during the period. Whipplewood Advisors LLC purchased a new stake in Intellia Therapeutics during the fourth quarter worth $40,000. Resona Asset Management Co. Ltd. purchased a new stake in Intellia Therapeutics during the fourth quarter worth $43,000. Jones Financial Companies Lllp boosted its position in Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock valued at $45,000 after acquiring an additional 2,280 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in shares of Intellia Therapeutics by 80.6% in the 4th quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock valued at $60,000 after acquiring an additional 2,299 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.
Intellia Therapeutics Price Performance
Intellia Therapeutics stock traded down $0.32 during midday trading on Friday, reaching $9.15. The company had a trading volume of 890,828 shares, compared to its average volume of 2,552,158. The company has a market capitalization of $947.27 million, a P/E ratio of -1.68 and a beta of 2.33. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $28.18. The firm's fifty day simple moving average is $7.98 and its 200-day simple moving average is $10.63.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. During the same quarter last year, the business earned ($1.12) EPS. The business's revenue was down 42.6% compared to the same quarter last year. On average, analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
NTLA has been the subject of a number of analyst reports. Wolfe Research upgraded Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective for the company in a research note on Monday, April 21st. Chardan Capital restated a "buy" rating and issued a $68.00 price target on shares of Intellia Therapeutics in a report on Friday, May 9th. Wall Street Zen upgraded shares of Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. Citigroup reduced their price target on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Finally, Truist Financial lowered their price target on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $36.90.
Get Our Latest Research Report on Intellia Therapeutics
About Intellia Therapeutics
(
Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Featured Stories
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
